Thu. Apr 22nd, 2021


Sputnik V has 91.6% efficacy in Russian trials: Lancet studyHYDERABAD: Even as Russian Covid-19 vaccine Sputnik V is eyeing an emergency use authorisation (EUA) rollout in India in March, medical journal Lancet has said the vaccine has shown an efficacy of 91.6% against symptomatic Covid-19 in a two-dose regimen.

The peer-reviewed journal published interim analysis data of Phase III trials of the vaccine involving over 20,000 adults in Russia on Tuesday. It also tweeted that a sub-analysis of over 2,000 participants aged over 60 years suggested the vaccine was similarly effective and well tolerated in the elderly as well.

A top Dr Reddy’s Laboratories official recently said the company hopes to complete the Indian leg of the clinical trials by February end and roll out Sputnik V in EUA mode in March after approval from the Indian drug regulator Drugs Controller General of India.

Follow and connect with us on , Facebook, Linkedin





Source link